|Bid||93.38 x 800|
|Ask||93.50 x 1100|
|Day's Range||93.40 - 94.92|
|52 Week Range||70.89 - 94.92|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||16.79|
|Earnings Date||Jul 28, 2022|
|Forward Dividend & Yield||2.76 (2.95%)|
|Ex-Dividend Date||Mar 14, 2022|
|1y Target Est||96.06|
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Rates could spike sooner rather than later. Prepare your portfolio.